Last reviewed · How we verify
YAZ®
YAZ is an oral contraceptive that prevents ovulation through a combination of ethinyl estradiol (estrogen) and drospirenone (progestin), while drospirenone also provides antimineralocorticoid activity.
YAZ is an oral contraceptive that prevents ovulation through a combination of ethinyl estradiol (estrogen) and drospirenone (progestin), while drospirenone also provides antimineralocorticoid activity. Used for Contraception, Acne vulgaris (FDA-approved indication), Premenstrual dysphoric disorder (PMDD).
At a glance
| Generic name | YAZ® |
|---|---|
| Also known as | Drospirenone/Ethinyl Estradiol (generic name), 3mg drospirenone/ 0.02mg ethinyl estradiol |
| Sponsor | Teva Pharmaceuticals USA |
| Drug class | Oral contraceptive (combined estrogen-progestin) |
| Target | Progesterone receptor, estrogen receptor, mineralocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Contraception / Gynecology |
| Phase | FDA-approved |
Mechanism of action
The estrogen and progestin components suppress the luteinizing hormone (LH) and follicle-stimulating hormone (FSH) surges needed for ovulation. Drospirenone, a fourth-generation progestin with antimineralocorticoid properties, also thickens cervical mucus and alters the endometrium to prevent fertilization and implantation. The antimineralocorticoid activity may help reduce water retention and bloating associated with traditional oral contraceptives.
Approved indications
- Contraception
- Acne vulgaris (FDA-approved indication)
- Premenstrual dysphoric disorder (PMDD)
Common side effects
- Nausea
- Headache
- Breast tenderness
- Breakthrough bleeding
- Mood changes
- Venous thromboembolism
Key clinical trials
- A Drug-Drug Interaction Study Between HS-10374 Tablets and Drospirenone and Ethinyl Estradiol Tablets(Yasmin®) (PHASE1)
- A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood (PHASE1)
- A Study to Evaluate the Effectiveness of NuvaRing® to Prevent Pregnancies in Chinese Women (P06450) (PHASE3)
- Drospirenone (3 mg) + Ethinyl Estradiol (0.02 mg) Tablets Relative to Yaz® (PHASE1)
- Drospirenone (3 mg) + Ethinyl Estradiol (0.03 mg) Tablets Relative to Yasmin® (PHASE1)
- E4/DRSP Ovarian Function Inhibition Study (PHASE2)
- A Prospective Multicenter Study on Patients'Satisfaction With Angeliq® Micro in Real Clinical Practice Conducted in Russia
- Comparison of Levonorgestrel Intrauterine System, Copper T Intrauterine Device and Oral Contraceptives on Life Quality (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |